Race Oncology Ltd (AU:RAC) — Market Cap & Net Worth
Market Cap & Net Worth: Race Oncology Ltd (RAC)
Race Oncology Ltd (AU:RAC) has a market capitalization of $341.71 Million (AU$482.94 Million) as of May 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #14415 globally and #378 in its home market, demonstrating a -10.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Race Oncology Ltd's stock price AU$2.65 by its total outstanding shares 182240542 (182.24 Million). Analyse how efficiently does Race Oncology Ltd generate cash to see how efficiently the company converts income to cash.
Race Oncology Ltd Market Cap History: 2016 to 2026
Race Oncology Ltd's market capitalization history from 2016 to 2026. Data shows growth from $24.50 Million to $341.71 Million (26.47% CAGR).
Index Memberships
Race Oncology Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$1.97 Trillion | 0.02% | #256 of 495 |
Weight: Race Oncology Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Race Oncology Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Race Oncology Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
58.25x
Race Oncology Ltd's market cap is 58.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $24.50 Million | $16.98K | -$318.00K | 1442.87x | N/A |
| 2017 | $56.74 Million | $25.21K | -$4.17 Million | 2250.56x | N/A |
| 2018 | $9.67 Million | $170.26K | -$6.31 Million | 56.80x | N/A |
| 2019 | $24.50 Million | $228.50K | -$3.66 Million | 107.22x | N/A |
| 2020 | $225.66 Million | $159.37K | -$3.85 Million | 1415.92x | N/A |
| 2021 | $464.21 Million | $387.38K | -$6.34 Million | 1198.31x | N/A |
| 2022 | $259.18 Million | $707.81K | -$11.20 Million | 366.18x | N/A |
| 2023 | $108.32 Million | $3.13 Million | -$9.92 Million | 34.56x | N/A |
| 2024 | $174.08 Million | $4.00 Million | -$13.82 Million | 43.49x | N/A |
| 2025 | $352.02 Million | $6.04 Million | -$4.79 Million | 58.25x | N/A |
Competitor Companies of RAC by Market Capitalization
Companies near Race Oncology Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Race Oncology Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Race Oncology Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Race Oncology Ltd's market cap moved from $24.50 Million to $ 341.71 Million, with a yearly change of 26.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$341.71 Million | -2.93% |
| 2025 | AU$352.02 Million | +102.22% |
| 2024 | AU$174.08 Million | +60.71% |
| 2023 | AU$108.32 Million | -58.21% |
| 2022 | AU$259.18 Million | -44.17% |
| 2021 | AU$464.21 Million | +105.71% |
| 2020 | AU$225.66 Million | +821.05% |
| 2019 | AU$24.50 Million | +153.33% |
| 2018 | AU$9.67 Million | -82.95% |
| 2017 | AU$56.74 Million | +131.58% |
| 2016 | AU$24.50 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Race Oncology Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $341.71 Million USD |
| MoneyControl | $341.71 Million USD |
| MarketWatch | $341.71 Million USD |
| marketcap.company | $341.71 Million USD |
| Reuters | $341.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Race Oncology Ltd
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across vari… Read more